| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary development focus |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 |
Form 4: Coastlands Capital Lp, 10% owner
Bought 50,000 shares ($319K) |
| 06 Nov 2026 |
Form 3: Coastlands Capital Lp, 10% owner
Holds 412,416 shares of Common Stock |
| 06 Nov 2026 | SCHEDULE 13G |
| 27 Oct 2026 |
Form 4: Gujrathi Sheila, Director
Received 85,821 shares as a grant or award · Acquired 3,259.707 Series D Preferred Stock (Other Transaction) |
| 27 Oct 2026 |
Form 3: Gujrathi Sheila, Director
No securities owned |
| 23 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +6 more
PRINCE MERGER SUB II, LLC, a Delaware limited liability company; |
| 06 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
On October 1, 2026, Bolt Biotherapeutics, Inc. (the “Company”) entered into the Second Amendment to Lease (the “Second Lease Amendment”) with HCP LS Redwood City LLC, as landlord (the “Landlord”). The Second Lease Amendment amends that c... |
| 21 Sep 2026 |
Form 4: Yonehiro Grant, Chief Operating Officer
Sold 1,417 shares ($5.35K) · Sold 4,909 shares ($16.3K) · Sold 6,850 shares ($22.2K) |
| 21 Sep 2026 |
Form 4: Nemec Sarah, Senior VP, Finance and PAO
Bought 509 shares ($1.97K) · Sold 843 shares ($3.18K) · Sold 2,922 shares ($9.7K) · 1 more |
| 21 Sep 2026 |
Form 4: Quinn William P., Director
Bought 637 shares ($2.47K) · Sold 1,889 shares ($7.13K) · Sold 6,545 shares ($21.7K) · 1 more |
| 13 Aug 2026 | SCHEDULE 13G |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results |
| 11 Jun 2026 |
Form 4: Berner Laura, Director
Granted 5,000 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Laporte Kathleen, Director
Granted 5,000 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Dupont Jakob, Director
Granted 5,000 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: O'callaghan Brian, Director
Granted 5,000 Stock Option (Right to Buy) |
Loading...